Abstract
Introduction and development. Natalizumab is a monoclonal antibody targeted against alpha-4 integrin that has proved to be very effective in the treatment of multiple sclerosis. The results of clinical trials published to date show a significant reduction in the rate of outbreaks and a decrease in the progression of the disability and of the disease activity as measured by means of magnetic resonance imaging. Natalizumab is well tolerated, although severe side effects have been reported that have conditioned its use as a second-line drug for the treatment of multiple sclerosis in patients who do not respond to conventional immunomodulators. Conclusions. The latest data in patients with these characteristics continue to show that natalizumab still offers a very good effectiveness and safety profile. This review examines the latest data oil the response to natalizumab in patients who fail to respond to therapy with conventional drugs. [REV NEUROL 2009; 49: 265-9]
| Original language | English |
|---|---|
| Pages (from-to) | 265-269 |
| Number of pages | 5 |
| Journal | Revista de neurologia |
| Volume | 49 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Sept 2009 |
Keywords
- Effectiveness
- Immunomodulators
- Integrin
- Multiple sclerosis
- Natalizumab
- Progressive multifocal leukoencephalopathy